Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy.

Mazzucchelli R, Barbisan F, Tagliabracci A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R.

Virchows Arch. 2007 Apr;450(4):371-8. Epub 2007 Feb 7.

2.

Detection of cancer in radical prostatectomy specimens with no residual carcinoma in the initial review of slides.

Duffield AS, Epstein JI.

Am J Surg Pathol. 2009 Jan;33(1):120-5. doi: 10.1097/PAS.0b013e318185723e.

PMID:
18971774
4.

Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.

Sung MT, Jiang Z, Montironi R, MacLennan GT, Mazzucchelli R, Cheng L.

Hum Pathol. 2007 Feb;38(2):332-41. Epub 2006 Nov 28.

PMID:
17134736
5.

Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy.

Kusumi T, Koie T, Tanaka M, Matsumoto K, Sato F, Kusumi A, Ohyama C, Kijima H.

Pathol Int. 2008 Nov;58(11):687-94. doi: 10.1111/j.1440-1827.2008.02294.x.

PMID:
18844933
6.

Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate.

Molinié V, Fromont G, Sibony M, Vieillefond A, Vassiliu V, Cochand-Priollet B, Hervé JM, Lebret T, Baglin AC.

Mod Pathol. 2004 Oct;17(10):1180-90.

8.

Can pT0 stage of prostate cancer be predicted before radical prostatectomy?

Descazeaud A, Zerbib M, Flam T, Vieillefond A, Debré B, Peyromaure M.

Eur Urol. 2006 Dec;50(6):1248-52; discussion 1253. Epub 2006 Jun 21.

PMID:
16828964
9.

Efficacy of androgen deprivation therapy for localized prostate cancer: analysis of pT0 evaluated by radical prostatectomy specimen.

Kadono Y, Yaegashi H, Izumi K, Ueno S, Kitagawa Y, Mizokami A, Asahi H, Kobashi K, Koshida K, Namiki M.

Anticancer Res. 2013 Mar;33(3):1147-51.

PMID:
23482794
10.
12.
13.

Stage pT0 after radical prostatectomy: a diagnostic dilemma.

Schirrmacher S, Kallidonis P, Horn LC, Nenning H, Rassler J, Rai B, Do M, Liatsikos E, Stolzenburg JU.

World J Urol. 2015 Sep;33(9):1291-6. doi: 10.1007/s00345-014-1441-z. Epub 2014 Nov 23.

PMID:
25417181
14.

Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy.

Carswell BM, Woda BA, Wang X, Li C, Dresser K, Jiang Z.

Histopathology. 2006 May;48(6):668-73.

PMID:
16681682
15.

Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy?: data from the CAPSURE database.

Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, Carroll PR.

Urology. 2000 Sep 1;56(3):430-5.

PMID:
10962308
16.

Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.

Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI.

Am J Surg Pathol. 2008 Mar;32(3):461-7. doi: 10.1097/PAS.0b013e318157020e.

PMID:
18300803
17.

Stage pT0 after radical prostatectomy with previous positive biopsy sets: a multicenter study.

Bessède T, Soulié M, Mottet N, Rebillard X, Peyromaure M, Ravery V, Salomon L; Cancerology Committee of the French Urological Association.

J Urol. 2010 Mar;183(3):958-62. doi: 10.1016/j.juro.2009.11.016. Epub 2010 Jan 18.

PMID:
20083270
19.

Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings.

Karram S, Trock BJ, Netto GJ, Epstein JI.

Am J Surg Pathol. 2011 Sep;35(9):1351-5. doi: 10.1097/PAS.0b013e3182217b79.

PMID:
21836493
20.

Supplemental Content

Support Center